Major deals

Pfizer and BioNTech have entered into an agreement with the UK to supply 30 million doses of candidate BNT162 mRNA-based vaccine against coronavirus. Delivery will only take place if clinical trials are successful and the drug is approved by the regulator. Financial details of the transaction are not disclosed, but are based on delivery dates and dose volumes.